Vor Biopharma

VORPhase 3

Vor Biopharma is pioneering a new approach to autoimmune disease by targeting the upstream drivers of B cell dysfunction with its lead asset, telitacicept. The company has a validated path forward, with telitacicept already approved and marketed for three indications in China and a broad global pipeline targeting over a million potential patients in the US alone. Led by an experienced team, Vor Bio is positioned to become a global leader in targeted autoimmune therapeutics, moving beyond symptom control to deliver durable, disease-modifying benefits.

Market Cap

$499.9M

Focus

Cell & Gene Therapy

VOR · Stock Price

USD 12.04123.56 (-91.12%)

Historical price data

AI Company Overview

Technology Platform

A TACI-Fc fusion protein platform designed for dual inhibition of the BAFF and APRIL cytokines, which are key upstream drivers of pathogenic B cell survival and autoantibody production in autoimmune diseases.

Pipeline Snapshot

6 drugs in pipeline, 4 in Phase 3

Drug	Indication	Stage
Telitacicept + Placebo	Systemic Lupus Erythematosus	Phase 3
Telitacicept + Placebo	Generalized Myasthenia Gravis	Phase 3
Telitacicept + Placebo	Primary Sjogren's Disease	Phase 3
Telitacicept + Placebo	Systemic Lupus Erythematosus	Phase 3
VCAR33	Leukemia, Myeloid, Acute	Phase 1/2

Funding History

Total raised: $307M

IPO$150MUndisclosedFeb 15, 2021

Series B$110MRA Capital ManagementJan 15, 2020

Series A$42M5AM VenturesMay 15, 2018

Seed$5M5AM VenturesJun 15, 2016

Opportunities

The primary growth opportunities are the successful global approval and launch of telitacicept in Myasthenia Gravis and Primary Sjögren's Disease, representing large, underserved markets.

Further expansion lies in leveraging the dual BAFF/APRIL mechanism across the broad pipeline of over ten additional autoimmune indications, where the drug has shown promise in China.

Risk Factors

Key risks include clinical trial failure in the pivotal global Phase 3 programs, regulatory hurdles in the US/EU, intense competition in the autoimmune space, and the company's dependence on the success of a single asset, telitacicept.

Competitive Landscape

Vor Bio competes with BAFF-only inhibitors like belimumab, CD20-depleting therapies, FcRn antagonists, and other B-cell modulators. Its key differentiation is the dual inhibition of BAFF and APRIL, which may offer superior efficacy in IgA-driven diseases and a validated clinical profile from its commercial experience in China.

Publications

Patents

Pipeline